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The Responsibilities ofPropofol-Induced Sedation during 
Endoscopies in relation to BIS® Monitored Anesthesia Depth 
Douglas D. Wellons 
In coordination with UT Medical Center and Dr. Steve K. Patteson 
Abstract 
Gastroenterologists and anesthesiologists have a rigorous and ongoing debate 
about the use of propofol during endoscopies. The question is who should be in charge of 
giving the dosing for procedures. A BIS® monitor calculates the depth of anesthesia 
reached during sedation, and it is used in this study to compare propofol' s strength to that 
of general anesthesia It was shown that propofol does induce similar levels of 
consciousness during sedation: 82% of the time patients were recorded to be at levels 
coinciding or exceeding general anesthesia with a minimum level of 5 in one patient. 
This study supports the theory that a person trained in general anesthesia should be 
responsible to closely monitor the drug. 
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The Responsibilities of Propofol-Induced Sedation during Endoscopies in relation to 
BIS® Monitored Anesthesia Depth 
Medicine is a dynamic field that is meant to change, or progress, towards an 
ultimate goal of extending life through advances in medical prevention, medical 
treatment, patient safety, and patient comfort. Unfortunately, these categories come under 
fire when the cost of care is involved, and compromises must be routinely made. 
Recently, there has been a widespread debate over a topic that encompasses each of these 
categories. The debate argues which medical personnel, anesthesia or gastrointestinal, 
should be in control of administering propofol during endoscopy procedures, and whether 
or not insurance will cover expenses. Propofol is a relatively new drug, approved by the 
FDA in 1989, for sedation purposes, but it is gaining quickly in popularity as the drug of 
choice for gastrointestinal (GI) endoscopy procedures (Aisenberg, 2006). The current 
proble~ is the FDA has a statement on the label that reads, "Pr?pofol injectable emulsion 
should be administered only by persons trained in the administration of general 
anesthesia and not involved in the conduct of the surgical/diagnostic procedure (FDA, 
2003, Fig. 1 )." Propofol was assigned this label because of its specific drug 
characteristics. Propofol is an isopropylphenol thought to interact with the inhibitory 
neurotransmitters of the brain, gamma-aminobutyric acid receptors (Bhandari, 2006). 
"The use of propofol for procedural sedation raises safety concerns because of its rapid 
action, pharmacokinetic and pharmacodynamic variability, and lack of a pharmacologic 
antagonist. Because propofol has no analgesic properties, relatively large doses are 
required when it is administered alone, and most patients are deeply sedated at some 
point during the endoscopic procedure (Aisenberg, 2006)." There is no reversal agent to 
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propofol, and, therefore, errors have to be treated by ventilatory and sometimes 
cardiovascular support (Flowers, 2006). Nurse administered propofol sedation (NAPS) is 
the administration of propofol by nurses with no formal anesthesia training in an attempt 
to cut costs, and it has full backing by gastroenterologists (Weaver, 2006). In contrast, 
anesthesiologists disagree with NAPS because of their lack of training (Aisenberg, 2006). 
The successes ofpropofol and the FDA's label have created three sides to the argument: 
anesthesiologists, endoscopists, and insurance companies. 
Anesthesiologists are in support of the label, and they want their services involved 
whenever propofol is used. Anesthesiologists are most concerned with patient safety, and 
this concern has caused them to take this stance (Flowers, 2006). The American Society 
for Anesthesiology (ASA) has explained that propofol should be restricted only to those 
experienced in the skills that are required during general anesthesia; for example, 
endotracheal intubation (Aisenberg, 200?). Propofol is a potent drug that is able to 
depress cardiovascular and respiratory systems, and it needs to be monitored by those 
aware of its capabilities (Flowers, 2006). As of today, the errors involving propofol have 
been few, but their occurrences still appear. For example: 
• According to the Pennsylvania Patient Safety Reporting System, over 100 error 
reports in which the use of propofol was cited have been reported, and sixteen 
percent of these were serious events including four deaths (patient Safety 
Advisory, 2006). 
• In a study of33,854 patients, there were 153 deaths. Three of these deaths (0.65%) 
were attributable to sedation (Leslie, 2005). 
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• A study of 2574 cases showed that 43 patients attained hypoxemia, and another 
six needed mask ventilation (Weaver, 2006). 
• Out of9152 patients, there were seven people that needed additional help. Three 
were laryngospasms, three were prolonged apnea, and one aspiration required 
hospitalization. 
• "There is a risk of bradycardia-related death during propofol administration which 
has been reported to be 1.4 in 100,000 patients. Propofol also produces dose-
dependent depression of ventilation and causes apnea in approximately 25% to 
35% of patients (Bhandari, 2006)." 
• In a separate study of 27,500 patients, 6.7% developed hypoxemia with severe 
hypoxemia in 141 people, 6.2% required oxygen administration, and there was a 
decline in blood pressure with 3.5% of colonoscopies and 1.2% of upper 
endoscopies (Tohda et al., 2006). 
• During 5,928 EODs and 11,683 coloscopies, there was an 11.7 / 1,000 ratio 
among cases for cardiopulmonary events (Vargo et al., 2006). 
Anesthesiologists believe that, because of the incidents and the risk associated with 
propofol sedation, their presence is required. Anesthesiologists are trained to react to any 
medication error or adverse effects during medical procedures. A transition towards 
NAPS may tarnish the record of propofol by increasing these medical errors, which 
would be a preventable risk. "Jo Harbaugh, an RN, was concerned about NAPS because 
rescuing patients from deep sedation using advanced airway management techniques has 
not always been the customary practice of nurses in :freestanding GI centers and office 
settings (Flowers, 2006)." Anesthesiologists stand firm in their opinion over propofol 
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administration, and they will continue to fight to keep the FDA's warning label intact on 
the propofol bottle. 
This label has gained considerable opposition from gastrointestinal groups, who 
support NAPS, and they are seeking its removal. "Gastrointestinal endoscopy is one of 
the most common interventional medical procedures performed throughout the world 
(Leslie, 2005)." Surveys show that propofol sedation is now present in 26% of the United 
States endoscopies (Aisenberg, 2006). A major reason this number has not grown even 
higher is due to the requirement for anesthesiologists during endoscopic procedures. "The 
American College of Gastroenterology petitioned the Food and Drug Administration to 
remove the warning from the product label for propofol, arguing that substantial clinical 
evidence establishes that propofol can be administered safely, effectively, and cost-
effectively by gastroenterologists and by nurses working under their supervision 
(Aisenberg, 2006)." Much of their stance is based on the belief that NAPS has, so far, 
been relatively safe, and they can go along without specialized anesthesia help. In two of 
the studies mentioned above (9,152 cases and 2,574 cases), there were no intubations and 
no deaths (Weaver, 2006). There were variations, but the supporters of NAPS argue that 
nothing was severe enough to warrant the necessity of an anesthesiologist. Including an 
anesthesiologist causes heightened costs of endoscopy procedures, and economists are 
scrutinizing this (Aisenberg, 2006). They say that the money per life-year saved versus 
anesthesiologist cost will only be cost effective if the anesthesiologist saves one patient 
life for every 5000 cases (Aisenberg, 2006). This high a rate of involvement has not been 
seen, and it probably never will. Gastroenterologists are worried they are missing out on 
the wonderful benefits of propofol, and this requirement is causing many to stick to 
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traditional drugs during endoscopies. Gastroenterologists will continue to support NAPS 
by finding safe methods to administer propofol without an anesthesiologist present. 
Insurance providers are the final factor in the administration of propofol dispute, 
and they develop their position largely on the views of the preceding arguments. 
Anesthesiologists are increasing the cost of a typical GI procedure with their presence 
associated with the use of propofol. Since many gastroenterologists have argued and 
shown they can get by without an anesthesiologist, insurers are ceasing their 
reimbursement of these doctors. "During the past decade, a number of insurance carriers 
also enacted policies restricting reimbursement to anesthesiologists during endoscopy to 
circumstances in which the patient is hard to sedate or clinically unstable (Aisenberg, 
2006)." As fewer insurers are willing to pay anesthesiologists, patients are less able to see 
doctors who administer propofol unless they are willing to payout of their own pocket. 
Propofol is the preferred drug for many patients, GI physicians, and nurses (Flowers, 
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2006). "Once you go propofol, you don't go back (Flowers, 2006)." Insurers add fuel to 
the fire between anesthesiologists and gastroenterologists because losing their support 
means losing patients, and although propofol may be preferred, many people must adhere 
to the health options that fit their finances. Insurers hold to the position that saves them 
money, and this debate is no different. 
What is the correct side of this argument, and where should we stand? All sides 
present valid facts toward a correct way to handle propofol and use it for the benefit of all, 
but there is only one way to answer the propofol question; either there is an 
anesthesiologist involved or there is not. The purpose of the label on propofol is to 
restrict its use to those specialized in general anesthetics. General anesthetics affect many 
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parts of the body simultaneously, and the anesthesiologist is present to monitor the 
various body parameters while other doctors can perform the specific procedure. The 
purpose of this study was to show that propofol is as potent a drug as general anesthetics 
in regards to levels of consciousness as measured by a Bispectral Index® (BIS®) system. 
The null hypothesis states that propofol infusion will not create the same BIS® levels as 
general anesthesia. This study will gather data to determine if trained anesthesia 
personnel are required for treatment with propofol. 
Methods 
Participants 
After IRB approval, any adult undergoing routine upper or lower endoscopic 
procedures will be included in this study. These patients will be consented in the order 
they arrive at the hospital, and they will not be randomized. The only factor used to 
exclud~ patients is age «18) because of problems involving inf~rmed consent and minors. 
Informed consent is a vital part of this study, and it must be obtained before any person is 
admitted to the study. Informed consent is meant to protect human patient rights and to 
maintain ethical values in research. Informed consent is obtained by explaining certain 
parameters of the study to the patient: research study goal, patient involvement, risks 
involved, future benefits, any changes in health care, and assure confidentiality. In this 
study, the goal is to decide whether persons trained in anesthetics should be in charge of 
propofol delivery. Patients participate by having a BIS® monitor sticker placed on their 
forehead during the endoscopy. The only risk may involve a slight rash from the adhesive 
of the sticker, and no changes to the regular healthcare occur by participating in this 
research. The only motivation for participants in the study would be the hope to help 
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future individuals through improved health care. All records are confidential, and 
patients' names will not be used in any pUblication. A goal of two hundred patients is to 
be obtained to fmalize the project with statistical support. 
Apparatus 
The items used to complete this study will be described in order of their use 
during a typical session. The Bispectral Index® (BIS®) system is the principal tool used to 
conduct the research study (Fig. 5). The BIS® system is comprised of five separate pieces: 
BIS® sensor, patient interface cable, digital signal converter, BIS® engine, and the display 
monitor. These are all connected to send the measured data to the display. 
"The BIS® sensor is a sophisticated electrode system specifically designed 
to work with BIS® systems. The raw EEG is transmitted from the sensor 
through the patient interface cable to the digital signal converter. The 
digital signal converter receives, amplifies and digitizes the raw EEG 
signal for subsequent processing and analysis. The BIS® engine, the heart 
of the BIS® system, contains the microprocessor responsible for rapid 
signal processing and computation of the BIS® Index. All BIS® systems 
are linked to display monitors [ ... ] with the ability to display a BIS® value, 
BIS® trends and important additional data (Kelley, 2003)." 
USB drives were used to transfer data from BIS® to office computers. Excel was used to 
store data and perform statistical operations. 
Procedure 
When a patient would arrive in the endoscopy suite of the hospital, their consent 
would be obtained. After consent, patients would be rolled into the procedure room, and 
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the BIS® sensor would be positioned on the for~head (Fig. 5). The sensor would be 
connected to the display monitor which had the BIS® number blocked from the 
anesthesiologist to blind the study. The machine would be switched on with the start of 
the procedure. Patients would be emolled and collected all day. At the end of the day, 
data from the BIS® system would be downloaded onto USB flash drives. This data would 
be transferred to office computers where it was uploaded and saved with ExceL Data had 
to be screened to prevent overlapping cases, and it was purged of any data recorded on 
patients before the start of propofol injection. Statistical evidence was finally calculated 
with the data. 
Results 
The results are derived from a patient group of 202 participants. There was an 
average BIS® of 49.33 for the procedures. Of the participants, 182 (90.10%) had averages 
below 65, and 40 (21.98%) of these had averages below 40 (Fig. 3). During the full 
amount of time for every procedure, 82.26% of the time patients were below a BIS® of 
65, and 78 of the cases remained below 65 for the entire duration of the procedure (Fig. 
4). The lowest BIS® reached was a level of five for one patient. 
Discussion 
The BIS® index was the main tool for this study, and it is being used to determine 
the depth of anesthesia for propofol administration during endoscopies. The BIS® index 
is a scale from 0 to 100, and this correlates to flat lining and awake, respectively (Kelley, 
2003). The values collected were compared to values associated with general anesthesia 
in order to gauge propofol's strength. Standards developed from clinical trials range 
general anesthesia from 40 to 60 on the BIS® scale (Kelley, 2003, Fig. 2). If propofol can 
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be shown to fall within this range, it will create, additional support to suggest that an 
anesthesiologist's presence may be preferred with propofol-induced sedation during 
endoscopies. 
The number 65 was chosen to depict when patients were just beginning to enter a 
general anesthesia state. During an overwhelming majority of time (82%), patients were 
in the general anesthesia range, and there were many more that exceeded this level (Fig. 
3). The overall average for every procedure came out to be just 49.33. It is becoming 
apparent that propofol is able to induce states comparable to drugs used in general 
anesthesia. Once, a patient's BIS® level got close to flat lining, a zero level. BIS® 
monitored propofol administration can be strongly associated with general anesthesia 
levels. 
Propofol is shown to be a potent anesthetic that greatly benefits endoscopic 
'-"' procedures, but gastroenterologists and anesthesiologists disagree on its control during 
use. The null hypothesis of this study was greatly overturned, and propofol created deep 
levels of unconsciousness that either compared or exceeded general anesthesia's range. It 
is responsible to use an anesthesiologist during propofol infusion because of its strength. 
The FDA's label is an appropriate warning on the bottle, and propofol needs to be 
monitored to insure no medical errors accumulate with the drug's use in medicine. "There 
is no substitute for general anesthesia training and experience whenever deep sedation is 
administered (Weaver, 2006)." 
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PT# AVESIS MINSIS AVGSQ EMG %<65 
1 64.64 40 88.11 39.82 46.43 
....... 2 56.09 45 86.18 30.73 100.00 
3 52.13 34 81.40 31.40 100.00 
4 55.33 44 79.67 30.17 100.00 
5 57.00 45 68.13 34.25 87.50 
6 43.78 31 61.44 34.22 100.00 
7 56.29 28 90.65 29.88 94.12 
8 67.27 57 79.73 39.00 27.27 
9 56.85 36 85.25 34.15 95.00 
10 51.00 34 82.00 33.37 94.74 
11 38.60 28 75.80 36.80 100.00 
12 50.75 26 63.88 36.13 75.00 
13 60.29 42 77.14 35.86 71.43 
14 61.87 41 89.47 31.93 100.00 
15 63.77 45 85.85 30.31 76.92 
16 46.13 22 72.30 41.65 82.61 
17 66.86 58 83.71 35.71 42.86 
18 35.34 22 75.74 33.89 94.29 
19 51.95 29 88.21 38.54 84.62 
20 36.04 16 87.83 33.13 95.83 
21 49.53 35 87.79 35.26 100.00 
22 61.00 34 68.33 42.33 50.00 
23 50.42 27 70.11 30.68 94.74 
24 43.43 32 82.57 30.14 100.00 
25 70.11 46 86.19 38.44 40.74 
26 44.43 24 79.14 35.62 95.24 
....... 27 41.15 24 63.65 33.25 85.00 
28 35.45 21 64.42 30.87 100.00 
29 54.50 35 85.07 36.71 85.71 
30 60.14 34 81.41 32.36 63.64 
31 54.65 35 90.09 28.09 100.00 
32 50.29 33 87.54 28.97 88.57 
33 55.71 33 89.10 33.26 93.55 
34 48.63 32 78.13 38.94 100.00 
35 19.90 6 70.60 28.30 100.00 
36 34.93 24 80.00 35.43 100.00 
37 61.50 47 87.40 30.55 80.00 
38 56.10 34 80.00 37.70 70.00 
39 55.08 26 87.00 33.40 88.00 
40 58.16 7 82.65 33.03 38.71 
41 49.40 25 85.67 33.03 100.00 
42 52.57 32 70.43 33.43 100.00 
43 38.13 26 71.63 31.38 87.50 
44 28.50 21 64.17 36.17 100.00 
45 38.00 26 75.50 31.25 100.00 
46 44.71 32 79.06 32.71 100.00 
47 44.22 28 87.44 28.61 100.00 
48 69.00 40 91.13 41.75 31.25 
49 49.08 32 67.67 30.50 100.00 
50 52.13 26 72.74 34.10 70.97 
51 39.25 34 63.00 31.25 100.00 
~ 
52 28.75 11 74.06 32.88 100.00 
53 41.74 23 82.79 34.82 92.31 
'-" 54 67.40 43 68.40 44.80 40.00 
55 44.81 22 82.38 29.13 93.75 
56 59.00 24 48.00 45.75 '50.00 
57 68.00 40 78.36 43.18 54.55 
58 45.58 33 88.63 28.71 100.00 
59 48.89 33 91.70 30.89 92.59 
60 47.81 31 82.05 32.00 95.24 
61 54.67 31 86.83 31.33 91.67 
62 82.86 65 67.00 41.14 0.00 
63 42.80 21 77.80 30.00 100.00 
64 30.64 20 81.50 27.29 100.00 
65 32.53 20 73.35 29.94 100.00 
66 47.11 34 79.89 29.95 100.00 
67 62.27 49 83.45 31.36 90.91 
68 32.33 27 30.67 35.00 100.00 
69 28.48 22 83.92 27.68 100.00 
70 51.03 28 85.03 34.50 81.25 
71 71.67 65 45.00 38.00 0.00 
72 43.84 21 71.00 36.37 73.68 
73 53.00 33 72.87 32.07 93.33 
74 42.89 22 88.00 27.89 100.00 
75 57.47 39 85.53 29.89 84.21 
76 51.63 24 57.88 48.00 62.50 
77 40.95 28 89.19 28.76 100.00 
78 45.75 27 89.70 30.60 95.00 
,...., 79 45.24 25 92.89 29.83 100.00 
80 54.97 33 91.37 31.23 85.71 
81 31.18 23 81.82 28.36 95.45 
82 25.66 13 85.48 25.86 100.00 
83 30.05 21 83.89 27.95 94.74 
84 28.71 21 79.29 33.41 94.12 
85 44.17 32 61.83 34.50 100.00 
86 35.50 16 81.75 38.25 87.50 
87 50.81 25 80.50 39.50 62.50 
88 48.50 38 75.13 35.25 100.00 
89 56.66 36 91.88 29.78 90.63 
90 51.79 32 89.68 28.96 82.14 
91 38.88 28 76.50 29.25 100.00 
92 47.29 25 76.24 35.53 70.59 
93 39.00 24 72.35 31.76 94.12 
94 53.17 30 77.50 36.75 83.33 
95 30.04 21 81.04 31.26 100.00 
96 26.27 17 62.54 30.95 97.30 
97 32.63 22 81.25 29.50 100.00 
98 34.86 25 68.86 30.10 100.00 
99 45.80 27 80.72 29.08 92.00 
100 55.95 39 90.19 37.95 85.71 
101 76.83 65 88.94 45.94 0.00 
102 56.40 42 86.80 31.95 90.00 
103 56.25 45 57.00 37.00 100.00 
~ 
104 80.94 49 70.19 49.78 12.50 
105 63.50 45 80.90 37.30 50.00 
'-'" 106 46.05 35 87.86 27.91 100.00 
107 40.25 24 67.69 31.50 100.00 
108 51.48 23 82.81 39.62 66.67 
109 54.89 40 81.84 34.32 89.47 
110 41.50 31 83.94 27.44 ~100.00 
111 57.12 43 82.76 31.71 100.00 
112 64.80 45 66.50 33.90 50.00 
113 70.57 56 83.79 41.00 28.57 
114 38.14 24 51.86 41.00 100.00 
115 57.88 42 68.63 38.50 75.00 
116 54.42 31 85.08 30.33 100.00 
117 53.29 38 67.57 30.00 85.71 
118 41.25 25 82.44 34.50 87.50 
119 72.07 63 77.86 43.43 0.00 
120 55.10 36 86.45 30.80 90.00 
121 42.86 28 88.48 28.86 97.62 
122 47.00 39 76.00 38.00 100.00 
123 62.74 37 85.42 34.26 63.16 
124 51.40 31 70.00 30.90 80.00 
125 48.48 22 76.48 31.90 95.24 
126 63.78 42 87.94 36.00 50.00 
127 63.00 47 76.50 40.13 75.00 
128 32.17 22 70.33 30.67 100.00 
129 67.60 39 62.00 42.40 20.00 
130 31.62 23 78.54 31.38 100.00 
........ 131 38.33 24 53.67 37.17 100.00 
132 52.71 26 86.09 36.23 77.14 
133 30.31 23 69.94 38.50 100.00 
134 41.65 23 72.59 33.18 82.35 
135 58.43 41 87.29 42.79 71.43 
136 42.93 24 84.64 30.29 92.86 
137 54.36 35 83.79 35.29 100.00 
138 45.92 33 76.62 31.54 100.00 
139 61.00 45 93.50 30.69 81.25 
140 40.38 25 77.75 32.00 93.75 
141 47.96 23 88.09 30.35 100.00 
142 55.05 30 82.37 35.21 68.42 
143 56.35 42 87.47 33.76 100.00 
144 69.00 68 20.50 57.50 0.00 
145 40.08 23 79.53 33.03 100.00 
146 44.48 5 83.36 37.64 78.79 
147 41.22 31 90.22 28.67 100.00 
148 24.88 20 69.04 30.75 100.00 
149 46.63 29 88.63 30.46 100.00 
150 41.14 28 82.29 32.71 100.00 
151 53.34 31 78.29 35.29 76.32 
152 43.00 28 86.40 34.20 90.00 
153 29.75 20 84.95 29.70 100.00 
154 48.80 24 88.60 32.33 90.00 
155 60.93 44 84.29 35.21 92.86 
~ 
156 41.42 27 84.17 32.42 100.00 
157 53.27 29 79.64 40.55 63.64 
"-" 158 42.44 22 69.22 41.56 66.67 
159 41.82 25 84.12 30.82 94.12 
160 68.52 48 84.68 38.72 40.00 
161 50.50 32 79.92 32.33 100.00 
162 49.67 38 66.33 38.17 100.00 
163 58.35 29 75.38 43.31 57.69 
164 76.72 69 88.17 47.94 0.00 
165 41.68 24 78.79 30.76 97.06 
166 28.43 20 61.71 31.86 100.00 
167 47.29 24 82.52 31.67 95.24 
168 55.14 40 81.57 41.57 85.71 
169 26.52 21 73.00 30.00 100.00 
170 69.52 58 83.93 39.78 18.52 
. 
171 46.09 24 88.31 29.77 91.43 
172 59.23 46 85.23 29.23 100.00 
173 47.80 28 52.80 35.00 80.00 
174 45.06 30 84.41 32.18 94.12 
175 42.31 25 76.66 29.24 96.55 
176 42.15 26 88.69 32.35 100.00 
177 31.43 17 87.35 29.30 100.00 
178 72.04 52 85.43 48.65 8.70 
179 28.00 22 73.36 29.93 100.00 
180 53.27 41 80.40 28.20 100.00 
181 44.73 29 88.46 29.27 100.00 
182 49.55 24 80.05 35.65 75.00 
........ 183 41.59 24 84.94 31.65 94.12 
184 50.73 37 86.00 30.80 93.33 
185 52.25 42 78.50 29.38 100.00 
186 41.58 18 78.83 32.00 100.00 
187 62.44 47 82.00 34.81 75.00 
188 78.54 74 79.92 50.00 0.00 
189 50.81 36 90.94 31.81 90.32 
190 33.77 24 83.55 28.45 95.45 
191 76.85 67 87.10 41.20 0.00 
192 44.27 21 84.73 39.82 81.82 
193 53.67 29 72.33 40.33 66.67 
194 42.94 33 88.00 28.44 100.00 
195 45.58 30 83.83 28.75 91.67 
196 63.33 33 87.33 34.61 55.56 
197 64.82 30 76.36 45.55 27.27 
198 52.10 33 89.05 32.20 90.00 
199 56.83 25 57.17 44.83 50.00 
200 32.57 25 77.00 30.14 100.00 
201 44.00 16 87.62 34.62 100.00 
202 38.00 26 70.83 30.00 100.00 
AVERAGE 49.33 31.98 78.73 34.22 82.26 
#>65 20.00 %<65 82.26 AbsoluteMin 5 
40<#<65 142.00 %>65 17.74 
#<40 40.00 %=100 78.00 
~ 
